CEO Alberto Santagostino, who took the helm in November 2024, is looking to differentiate the Seattle-based company from other CDMOs targeting the biopharma industry.
The South Korean manufacturer and exporter of biosimilars said it is prepared to respond regardless of how the Trump administration’s drug tariff policy might be implemented.